- Revenue: $586.0M (Est. $538.2M) ✅; +111% YoY
- Adj EPS: $0.20 (Est. $0.12) ✅
- Net Income: $49.5M (Est. $28.2M) ✅; +346% YoY
- Adj EBITDA: $91.1M (Est. $61.3M) ✅; +182% YoY
- Gross Margin: 73% (Est. 77%) ❌
FY25 Guidance:
- Revenue: $2.3B–$2.4B (Est. $2.32B) ✅
- Adjusted EBITDA: $295M–$335M (Est. $297M) ✅
Q2 FY25 Guidance:
- Revenue: $530M–$550M
- Adjusted EBITDA: $65M–$75M
- Adjusted EBITDA Margin: 12%–14%
2030 Long-Term Targets:
- Revenue: At least $6.5B
- Adjusted EBITDA: At least $1.3B
Q1 Subscriber & Platform Metrics:
- Total Subscribers: 2.37M; UP +38% YoY
- Monthly Online Revenue per Avg Subscriber: $84; UP +53% YoY
Q1 Revenue Breakdown:
- Online Revenue: $576.4M; UP +115% YoY
- Wholesale Revenue: $9.6M; DOWN -7% YoY
Others:
- Free Cash Flow: $50.1M; UP +321% YoY
- Operating Cash Flow: $109.1M; UP +323% YoY
CEO Andrew Dudum's Commentary:
- "We’re starting 2025 with incredible momentum. Millions are turning to us for personal, affordable care. We’re building a future-ready platform that enables cross-industry collaboration with pharma, diagnostics, and providers to serve tens of millions."
CFO Yemi Okupe's Commentary:
- "Our subscriber base grew to 2.4M, with 1.4M using personalized solutions. Our 111% YoY revenue growth and rising engagement reaffirm our long-term growth across five levers: personalization, new specialties, enhanced care access, partnerships, and global expansion."
